Felix Couture
Overview
Explore the profile of Felix Couture including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
2809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma L, Titmuss E, Loree J, Jonker D, Kennecke H, Berry S, et al.
J Immunother Cancer
. 2024 Dec;
12(12.
PMID: 39631846
Background: Nutritional stress is a mechanism that allows tumor cells to evade the immune system. Arginine (ARG), an amino acid involved in immunomodulation, aids in regulating T-lymphocyte cell activity and...
2.
Brown J, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, et al.
J Natl Cancer Inst
. 2024 Aug;
116(12):2032-2039.
PMID: 39180477
Background: Inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset...
3.
Cho B, Brana I, Cirauqui B, Aksoy S, Couture F, Hong R, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1254.
PMID: 39054467
Background: Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits...
4.
Nowak J, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, et al.
J Clin Oncol
. 2024 Jun;
42(24):2853-2859.
PMID: 38889377
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...
5.
Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Hoffert C, Srivastava A, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203214
Single-agent regorafenib is approved in Canada for metastatic colorectal cancer (mCRC) patients who have failed previous lines of therapy. Identifying prognostic biomarkers is key to optimizing therapeutic strategies for these...
6.
Gabelli M, Perez-Martinez A, Bueno Sanchez D, Lucchini G, Grenier L, Couture F, et al.
Bone Marrow Transplant
. 2023 Dec;
59(2):288-290.
PMID: 38097758
No abstract available.
7.
Chen E, Loree J, Titmuss E, Jonker D, Kennecke H, Berry S, et al.
JAMA Netw Open
. 2023 Dec;
6(12):e2346094.
PMID: 38051531
Importance: Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer. Recent findings suggest the efficacy of ICIs may be modulated by the presence...
8.
Al-Mansor E, Mahoney M, Chenard-Poirier M, Ramjeesingh R, Nair V, Kennedy E, et al.
Curr Oncol
. 2023 Sep;
30(9):8172-8185.
PMID: 37754508
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023 was held in Quebec City, Quebec 2-4 February 2023. The purpose of the conference was to develop consensus statements on emerging...
9.
Brown J, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, et al.
Cancer
. 2023 Aug;
129(23):3724-3734.
PMID: 37651160
Background: One in three patients with stage III colon cancer will experience tumor recurrence. It is uncertain whether physical activity during and after postoperative chemotherapy for stage III colon cancer...
10.
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al.
J Clin Oncol
. 2023 Jul;
41(21):3663-3669.
PMID: 37459755
Purpose: To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic...